TMEM47 is a transmembrane protein with diverse roles in cancer progression and cellular processes. In hepatocellular carcinoma (HCC), TMEM47 expression is significantly upregulated in chemoresistant tumors, with higher levels observed in patients who do not respond to cisplatin-based transarterial chemoembolization treatment 1. TMEM47 overexpression promotes cisplatin resistance in HCC cells, while its targeted inhibition enhances cisplatin sensitivity by promoting caspase-mediated apoptosis and suppressing drug efflux mechanisms 1. The protein shows tissue-specific expression patterns, being specifically overexpressed in brain metastatic breast cancer cells alongside other neuronal transmembrane proteins 2. TMEM47 serves as a molecular marker in multiple cancer contexts: it is part of a cancer-associated fibroblast poor-prognosis gene signature in CMS4 colorectal cancer 3, functions as a rhabdomyosarcoma marker for detecting disseminated disease 4, and contributes to thyroid cancer recurrence prediction models 5. Additionally, TMEM47 has been identified as a potential biomarker for mesenchymal stromal cell characterization, helping distinguish MSCs from fibroblasts 6. In multiple sclerosis, TMEM47 is a target gene of hsa-mir-4423, suggesting involvement in immune-mediated neurological processes 7.